Results 41 to 50 of about 7,381 (220)
Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching [PDF]
, 2013 We recently introduced Drug Profile Matching (DPM), a novel virtual affinity fingerprinting bioactivity prediction method. DPM is based on the docking profiles of ca.
Czobor, P. +6 more
core +1 more source
Special Issue: “Molecules against Alzheimer”
Molecules, 2016 This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic ...
Michael Decker, Diego Muñoz-Torrero
doaj +1 more source
eLife, 2023 Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicate the ...
Ian R Outhwaite +5 more
doaj +1 more source
Polypharmacology of dopamine D1-like receptor antagonists [PDF]
Arhiv za farmaciju, 2015 Drug discovery based on development of selective ligands for a specific target intended to modulate its activity and revert pathophysiological process is now recognized as too simplistic to design effective agent for complex multifactorial diseases ...
Nikolić Katarina +2 more
doaj +1 more source
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Pharmaceuticals, 2022 Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by decreased synaptic transmission and cerebral atrophy with appearance of amyloid plaques and neurofibrillary tangles.
Siew Lee Cheong +6 more
doaj +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, EarlyView.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Structural and Functional View of Polypharmacology [PDF]
Scientific Reports, 2016 AbstractProtein domains mediate drug-protein interactions and this effect can explain drug polypharmacology. In this study, we associate polypharmacological drugs with CATH functional families, a type of protein domain and we use the network properties of these druggable protein families to analyse their relationships with drug side effects.
Moya García, Aurelio +7 more
openaire +3 more sources
Computational Drug Repurposing Using Power Graph Analysis of Integrated Drug-Target-Disease Network
IEEE Access, 2023 The drug discovery and development is a complex and expensive process, and the probability of success is low. Nowadays, the philosophy of drug discovery has been transformed from one-drug one-target to multiple-drug multiple-targets, called as ...
P. H. Nishamol +2 more
doaj +1 more source
Protein Functional Families to characterise drug-target interactions. [PDF]
, 2017 The quest for “magic bullets” has been the driving force in drug discovery during the last two decades. However, the increasing rate of drug failure over this period has occurred concurrently with the assumption that a drug is a selective ligand for a ...
Moya-García, Aurelio
core
Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies [PDF]
, 2016 Support was kindly provided by the EU COST Action CM1103. DA, KN, and JV kindly acknowledge national project number 172033 and OI1612039 supported by the Ministry of the Republic of Serbia.
Agbaba, Danica +7 more
core +3 more sources